Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 9:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 79 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: itraconazole 200 mg Clear all
Withdrawn Phase 1 Interventional Accepts healthy volunteers

An Open-label, Two-period, Fixed-sequence Study to Evaluate Multiple-dose Itraconazole Effect on The Single-dose PK of PF-06372865 in Healthy Subjects

NCT02475746
View directory record Official record
Conditions
Healthy
Interventions
PF-06372865, itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 2 Interventional Results available

Study Comparing SUBA™-Itraconazole With SPORANOX® (Itraconazole) in the Treatment of Onychomycosis

NCT00791219
View directory record Official record
Conditions
Onychomycosis
Interventions
SUBA-itraconazole, Itraconazole, Placebo
Drug
Lead sponsor
Halcygen Pharmaceuticals Limited
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
8
States / cities
Altamonte Springs, Florida • Miami, Florida • Boise, Idaho + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult Participants

NCT03173170
View directory record Official record
Conditions
Healthy Participants
Interventions
TAK-954, Itraconazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Effect of Multiple Doses of Itraconazole on the Drug Lu AF35700 in Healthy Young Men and Women

NCT03103646
View directory record Official record
Conditions
Cytochrome P450 Interaction
Interventions
Lu AF35700, Itraconazole (200 mg), Itraconazole (300 mg)
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study That Evaluates the Effect of CYP3A4 Inhibition on Lu AG06466 in Healthy Men and Women

NCT04405323
View directory record Official record
Conditions
Healthy
Interventions
Lu AG06466, Itraconazole
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect Of Itraconazole On The Pharmacokinetics Of Palbociclib

NCT02131298
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib Alone, Palbociclib plus itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2623091 in Healthy Participants

NCT02300259
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY2623091, Itraconazole, Simvastatin, Tadalafil, Diltiazem
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 1 Interventional Results available

Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels

NCT04537715
View directory record Official record
Conditions
All Malignancies, Advanced Malignancies, Hematologic Malignancy, Solid Tumor, Follicular Lymphoma (FL), Non-Hodgkin Lymphoma (NHL), Diffuse Large B-Cell Lymphoma (DLBCL), Epithelioid Sarcoma (ES), Synovial Sarcoma, Renal Medullary Carcinoma, Mesothelioma, Rhabdoid Tumor
Interventions
Tazemetostat, Itraconazole, Rifampin
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Encinitas, California • Los Angeles, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor

NCT03259542
View directory record Official record
Conditions
Drug Interaction Potentiation, Healthy
Interventions
Mifepristone 300 MG, Itraconazole 100 MG
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma

NCT02259010
View directory record Official record
Conditions
Advanced Solid Tumors, Relapsed/Refractory Lymphoma
Interventions
Alisertib, Itraconazole
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
St Louis, Missouri • Oklahoma City, Oklahoma • Germantown, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects

NCT03301181
View directory record Official record
Conditions
Healthy Volunteers: Asian, Non-Asian
Interventions
BGB-3111 (Arm A), Rifampin, BGB-3111 (Arm B), Itraconazole
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites

NCT03512548
View directory record Official record
Conditions
Healthy
Interventions
Relacorilant 350mg, Itraconazole, Relacorilant 300mg
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects

NCT02820935
View directory record Official record
Conditions
Pharmacokinetics
Interventions
CC-220, Rifampin, Itraconazole
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Oct 1, 2026, 9:31 PM EDT
Terminated Phase 2 Interventional Results available

A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.

NCT01752023
View directory record Official record
Conditions
Non-small Cell Lung Cancer Metastatic
Interventions
Cisplatin + Gemcitabine with SUBATM-itraconazole, Cisplatin + Gemcitabine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects

NCT04606537
View directory record Official record
Conditions
Healthy, Drug Drug Interaction
Interventions
Itraconazole, Rifampin, KBP-5074
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study

NCT05720767
View directory record Official record
Conditions
Relapsed or Refractory Lymphoma
Interventions
HMPL-523, Itraconazole, Rifampin
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 1 Interventional

Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole

NCT02824042
View directory record Official record
Conditions
Medical Oncology
Interventions
Anetumab ravtansine (BAY94-9343), Itraconazole
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Santa Monica, California • Detroit, Michigan • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label, 2 Treatment Period,Study To Study The Drug Interaction Between Repeated Doses Of Itraconazole And Single Dose Pharmacokinetics (PK) Of PF-06648671 In Healthy Adults.

NCT02883114
View directory record Official record
Conditions
Healthy
Interventions
PF-06648671, Itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of Itraconazole and Rifampicin on the Single-Dose Pharmacokinetics of JNJ-53718678 in Healthy Adults

NCT02729467
View directory record Official record
Conditions
Healthy
Interventions
JNJ-53718678, Itraconazole, Rifampicin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A

NCT03624959
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Ozanimod, Gemfibrozil, Itraconazole, Rifampin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 1 Interventional Results available

Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors

NCT02122770
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
MLN4924, Fluconazole, Itraconazole, Docetaxel, Carboplatin, Paclitaxel
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Atlanta, Georgia • St Louis, Missouri • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 1, 2026, 9:31 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3154885 in Healthy Participants

NCT04014361
View directory record Official record
Conditions
Healthy
Interventions
LY3154885 - Capsule, Placebo - Capsule, Itraconazole, LY3154885 - Tablet
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy Participants

NCT04901923
View directory record Official record
Conditions
Healthy Participants
Interventions
ACP-196, Itraconazole
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 1, 2026, 9:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Trial of AP31969 and Carbamazepine or Itraconazole

NCT07449390
View directory record Official record
Conditions
Healthy Participants
Interventions
AP31969, Carbamazepine, Itraconazole
Drug
Lead sponsor
Acesion Pharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 1, 2026, 9:31 PM EDT